GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China
GSK plc revealed an exclusive strategic partnership with Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aimed at supporting the launch and expansion of bepirovirsen in mainland China. Bepirovirsen, currently under priority regulatory review in China, is being developed as a potential first-in-class therapy for chronic hepatitis B (CHB).
As one of China’s leading hepatitis B players, CTTQ brings an extensive liver disease portfolio and a commercial network that spans over 5,000 healthcare institutions nationwi...
